ReviewExpert opinion on pharmacotherapy2016
Novel prevention strategies for bacterial infections in cirrhosis.
Review in Expert opinion on pharmacotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Periodontitis and Chronic Liver Disease: Mechanistic Insights Focusing onMicroorganisms · 2026Review
- Mapping the relationship between alcohol use disorder and gut microbiota: a 20-year bibliometric study.Frontiers in microbiology · 2024Article
- Impact of multidrug resistance on the management of bacterial infections in cirrhosis.World journal of clinical cases · 2023Review
- Preventing Bacterial Translocation in Patients with Leaky Gut Syndrome: Nutrition and Pharmacological Treatment Options.International journal of molecular sciences · 2022Review
- Plasticity of monocytes and macrophages in cirrhosis of the liver.Frontiers in network physiology · 2022Review
- From intestinal dysbiosis to alcohol-associated liver disease.Clinical and molecular hepatology · 2020Review
- Lymphocyte-To-Monocyte Ratio as the Best Simple Predictor of Bacterial Infection in Patients with Liver Cirrhosis.International journal of environmental research and public health · 2020Observational
- Current Status and Prospects of Spontaneous Peritonitis in Patients with Cirrhosis.BioMed research international · 2020Review
- Antimicrobial resistance in chronic liver disease.Hepatology international · 2020Review
- Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention.Therapeutic advances in gastroenterology · 2020Review
- Prophylactic Antibiotics in Cirrhosis: Are They Promoting or Preventing Infections?Clinical liver disease · 2019Review
- Emerging Gram-positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: A retrospective study.Experimental and therapeutic medicine · 2019Article
- Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.Frontiers in immunology · 2019Review
- Unresolved issues in the prophylaxis of bacterial infections in patients with cirrhosis.World journal of hepatology · 2018Article
- Disruption of the gut-liver axis in the pathogenesis of acute-on-chronic liver failure.European journal of gastroenterology & hepatology · 2018Review
- NOD2 gene variants confer risk for secondary sclerosing cholangitis in critically ill patients.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionBacterial infections are a serious complication of cirrhosis, as they can lead to decompensation, multiple organ failure, and/or death. Preventing infections is therefore very relevant. Because gut bacterial translocation is their main pathogenic mechanism, prevention of infections is mostly based on the use of orally administered poorly absorbed antibiotics such as norfloxacin (selective intestinal decontamination). However, antibiotic prophylaxis leads to antibiotic resistance, limiting therapy and increasing morbidity and mortality. Prevention of bacterial infections in cirrhosis should therefore move away from antibiotics. AREAS COVERED: This review focuses on various potentially novel methods to prevent infections in cirrhosis focusing on non-antibiotic strategies. The use of probiotics, nonselective intestinal decontamination with rifaximin, prokinetics and beta-blockers or fecal microbiota transplant as means of targeting altered gut microbiota, bile acids and FXR agonists are all potential alternatives to selective intestinal decontamination. Prokinetics and beta-blockers can improve intestinal motility, while bile acids and FXR agonists help by improving the intestinal barrier. Finally, granulocyte colony stimulating factor (G-CSF) and statins are emerging therapeutic strategies that may improve immune dysfunction in cirrhosis. EXPERT OPINION: Evidence for these strategies has been restricted to animal studies and proof-of concept studies but we expect this to change in coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.